BioNexus Gene Lab Corp.
BGLC
$5.38
-$0.04-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.93M | -2.12M | -1.60M | -941.60K | -2.21M |
| Total Depreciation and Amortization | 173.80K | 163.60K | 153.20K | 139.90K | 120.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -346.60K | -872.00K | -908.90K | -1.84M | -102.60K |
| Change in Net Operating Assets | 14.80K | -199.20K | 115.50K | -310.70K | -203.40K |
| Cash from Operations | -3.09M | -3.03M | -2.24M | -2.95M | -2.39M |
| Capital Expenditure | -233.80K | -214.10K | -226.90K | -223.80K | -158.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 500.60K | 572.80K | 605.00K | -1.32M | -1.56M |
| Cash from Investing | 267.00K | 358.80K | 378.10K | -1.54M | -1.72M |
| Total Debt Issued | -198.40K | -23.00K | 3.90K | 18.50K | 215.50K |
| Total Debt Repaid | -1.40K | -900.00 | -- | -- | -- |
| Issuance of Common Stock | 141.00K | 141.00K | 141.00K | 511.70K | 6.26M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4.10K | 4.60K | 4.60K | 4.40K | 4.20K |
| Cash from Financing | -54.70K | 121.70K | 149.50K | 534.60K | 6.48M |
| Foreign Exchange rate Adjustments | 413.90K | 155.80K | 40.30K | 496.90K | -167.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.47M | -2.39M | -1.67M | -3.46M | 2.20M |